University Clinical Center Nis, Clinic of Nephrology
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Giorgadze, Elene
DETECT, NCT04786873 / 2018-001989-42: A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is

Completed
3
101
Europe, US, RoW
Macimorelin, Macrilen, AEZS-130, Macimorelin GHST, Macimorelin test, Macrilen GHST, Macrilen test, Arginine, R-Gene 10, arginine test, arginine GHST, Clonidine, Catapressan 75, Clonidine test, Clonidine GHST
AEterna Zentaris, Novo Nordisk A/S
Growth Hormone Deficiency
06/24
06/24
NCT05514548 / 2022-002140-51: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Completed
2
265
Europe, Canada, US, RoW
INV-202, None applicable, Placebo
Inversago Pharma Inc., Worldwide Clinical Trials
Diabetic Kidney Disease
08/24
09/24
NCT04628481 / 2020-001926-71: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Active, not recruiting
2
140
Europe, US, RoW
Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo
Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a.
Recent Onset type1 Diabetes
04/24
04/26
Mitic, Branka
NCT05514548 / 2022-002140-51: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Completed
2
265
Europe, Canada, US, RoW
INV-202, None applicable, Placebo
Inversago Pharma Inc., Worldwide Clinical Trials
Diabetic Kidney Disease
08/24
09/24
NCT05540665 / 2022-001377-31: Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Terminated
2
19
Europe, US, RoW
Daxdilimab, Placebo (Normal Saline)
Amgen, Horizon Therapeutics Ireland DAC
Lupus Nephritis
01/24
01/24
PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended
2
279
Europe, US, RoW
zetomipzomib, KZR-616, placebo, matching placebo
Kezar Life Sciences, Inc.
Lupus Nephritis
05/26
07/26
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

Active, not recruiting
1
16
Europe, Japan, US, RoW
Mezagitamab, TAK-079
Takeda
Kidney Disease, Glomerulonephritis
03/26
03/26

Download Options